Browsing Tag
Kailera Therapeutics
2 posts
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Kailera Therapeutics priced its IPO at $16 to raise $625M. Read what the deal means for KLRA, obesity drug competition, and biotech funding now.
Are oral GLP-1 pills finally closing the credibility gap with injectables after ribupatide data
Are oral GLP-1 and GIP agonists becoming viable after ribupatide’s Phase 2 data? Explore what this shift means for obesity drug strategy.